0001415889-22-008769.txt : 20220817
0001415889-22-008769.hdr.sgml : 20220817
20220817160650
ACCESSION NUMBER: 0001415889-22-008769
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220815
FILED AS OF DATE: 20220817
DATE AS OF CHANGE: 20220817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Marucci Anthony S
CENTRAL INDEX KEY: 0001429933
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 221174041
MAIL ADDRESS:
STREET 1: 66 COLD HILL DRIVE
CITY: MENDAHM
STATE: NJ
ZIP: 07945
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
form4-08172022_010842.xml
X0306
4
2022-08-15
0000744218
Celldex Therapeutics, Inc.
CLDX
0001429933
Marucci Anthony S
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
true
true
false
false
PRESIDENT & CEO
Common Stock
2022-08-15
4
M
0
75000
2.78
A
102692
D
Common Stock
2022-08-15
4
M
0
45000
9.0165
A
147692
D
Common Stock
2022-08-15
4
S
0
120000
37.6631
D
27692
D
Incentive Stock Option
2.78
2022-08-15
4
M
0
75000
0
D
2029-06-19
Common Stock
75000
25000
D
Incentive Stock Option
9.0165
2022-08-15
4
M
0
45000
0
D
2028-06-13
Common Stock
45000
26665
D
Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
As of June 13, 2022, the option is fully vested.
/s/ Samuel B. Martin, attorney-in-fact for Anthony S. Marucci
2022-08-17